If you follow peptide research at all, you'll know that the biggest current wave of interest sits in one area: metabolism. Three names dominate the conversation — retatrutide, tirzepatide and cagrilintide — and they come up in search data more than almost everything else in the category. This guide explains what each compound is, how they differ, and why researchers find them so interesting. As always, this is educational material about research compounds — nothing here is dosing advice, and nothing here is a health claim.
WHY METABOLIC PEPTIDES DOMINATE THE LITERATURE
The story starts with incretin biology. Incretins are gut-derived hormones that signal to the pancreas and brain after eating, and over the last two decades they've become one of the most productive areas in the whole of peptide pharmacology. Each of the three compounds below works on a different slice of that system, which is exactly why researchers study them both alone and in combination.
RETATRUTIDE
Retatrutide is a synthetic peptide developed by Eli Lilly, currently in Phase 3 clinical trials. Its distinguishing feature is that it activates three receptors simultaneously:
- GIP receptor (glucose-dependent insulinotropic polypeptide)
- GLP-1 receptor (glucagon-like peptide-1)
- Glucagon receptor
Triple-receptor activity is what makes it novel — earlier compounds in this family activated one or two of these pathways, and retatrutide was designed to probe whether combined activation produces effects beyond what the single- and dual-agonists showed. The published Phase 2 data generated enormous attention in the research community, which is a large part of why "buy retatrutide" and similar searches have climbed steadily in the UK since.
TIRZEPATIDE
Tirzepatide is the dual agonist that preceded retatrutide — it activates the GIP and GLP-1 receptors, but not the glucagon receptor. It has been through the full clinical development pathway and is the reference compound most researchers now compare newer molecules against. In the lab, it matters because it represents the "two-pathway" benchmark: when a researcher wants to understand what the third (glucagon) pathway adds in retatrutide, tirzepatide is the natural control.
CAGRILINTIDE
Cagrilintide comes at the same problem from a completely different direction. Rather than the incretin system, it's a long-acting analogue of amylin — a hormone co-secreted with insulin that plays a role in satiety signalling and gastric emptying. It has been studied in combination with semaglutide in large clinical trials, and it matters to researchers for two reasons:
- it demonstrates that non-incretin pathways can contribute to the same research questions
- combination studies (cagrilintide plus an incretin agonist) are where much of the current literature is heading
If incretin agonists are the headline act, cagrilintide is the reason researchers pay attention to the supporting cast.
HOW TO JUDGE A METABOLIC RESEARCH PEPTIDE (FROM ANY SUPPLIER)
Interest in this category is high, and quality varies enormously between sources. Before you buy from anyone — including us — run this checklist:
1. Demand a batch-specific COA. It should show identity testing and purity matched to the batch number printed on your vial, from an independent laboratory.
2. Check the quantities on the label. "Retatrutide" without a stated milligram amount tells you nothing. You should see exact content per vial.
3. Be sceptical of appearance claims. A lyophilised cake should look like a clean white-to-off-white solid. Discolouration, crumbling, or moisture are warning signs.
4. Cold chain matters. These peptides should be stored refrigerated at 2-8°C in lyophilised form, protected from light.
5. Read the wording on the site. Any supplier making benefit claims for humans, or implying these are medicines or supplements, is a supplier to walk away from — research compounds are for laboratory research use only.
WHAT'S ACTUALLY BEING SEARCHED
One honest observation from our own shop's search data: queries like "best peptide for losing belly fat" and "retatrutide buy uk" now outnumber searches for most traditional research peptides. Whether that reflects researchers following the clinical literature or the wider public conversation around these molecules, the curiosity is real — and it makes the quality checklist above more important, not less. High demand attracts low-quality suppliers faster than any other category.
THE BOTTOM LINE
Retatrutide is the triple-pathway newcomer generating the headlines. Tirzepatide is the dual-pathway benchmark it gets compared against. Cagrilintide shows the question is bigger than the incretin system alone. All three are research compounds — supplied strictly for scientific and laboratory research applications, not for human use, and any supplier who tells you otherwise is one to avoid.
All compounds mentioned here are supplied strictly for scientific and laboratory research applications.